{
    "clinical_study": {
        "@rank": "109154", 
        "acronym": "FAIR", 
        "arm_group": {
            "arm_group_label": "Moderate-to-severe Crohn's disease", 
            "description": "Patients with moderate-to-severe Crohn's disease on Adalimumab induction therapy"
        }, 
        "biospec_descr": {
            "textblock": "Stool"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study aims to monitor fecal calprotectin (FC) level in moderate-to-severe Korean\n      Crohn's Disease (CD) patients on Adalimumab induction treatment."
        }, 
        "brief_title": "An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Crohn's disease patients:\n\n          1. Active luminal, moderate-to-severe Crohn's Disease with Crohn's disease activity\n             index (CDAI) > 220, who will start Adalimumab treatment in normal clinical practice\n             setting\n\n          2. Fecal Calprotectin (FC)  over 150 microgram/g.\n\n          3. Ileocolonic or colonic disease, with or without involvement of proximal\n             gastrointestinal areas.\n\n        2. Signed authorization form to use personal and/or health data prior to the entry into\n        the study.\n\n        Exclusion Criteria:\n\n          1. Disease patterns restricted to proximal (small bowel, gastroduodenal) GI areas.\n\n          2. Patients who have undergone colectomy other than ileocecal resection.\n\n          3. Pregnancy or breast feeding.\n\n          4. Contraindication to any anti-TNF agent\n\n          5. Any drug dependency."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "General hospital"
            }
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759264", 
            "org_study_id": "P13-974"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Fecal Calprotectin", 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "url": "http://rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ansan", 
                        "country": "Korea, Republic of", 
                        "zip": "425-707"
                    }, 
                    "name": "Site Reference ID/Investigator# 109795"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Site Reference ID/Investigator# 91900"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "705-717"
                    }, 
                    "name": "Site Reference ID/Investigator# 91901"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guri", 
                        "country": "Korea, Republic of", 
                        "zip": "471-701"
                    }, 
                    "name": "Site Reference ID/Investigator# 109815"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "405-760"
                    }, 
                    "name": "Site Reference ID/Investigator# 109775"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Site Reference ID/Investigator# 91893"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-710"
                    }, 
                    "name": "Site Reference ID/Investigator# 91898"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130-872"
                    }, 
                    "name": "Site Reference ID/Investigator# 91896"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Site Reference ID/Investigator# 91894"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136-705"
                    }, 
                    "name": "Site Reference ID/Investigator# 91899"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Site Reference ID/Investigator# 91895"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Site Reference ID/Investigator# 91897"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "zip": "442-723"
                    }, 
                    "name": "Site Reference ID/Investigator# 91873"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease While on Adalimumab Induction Therapy: a KoRean Experience (FAIR)", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Deborah  Chee, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with fecal calprotectin < 150 microgram/g", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with fecal calprotectin < 150 microgram/g", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Percentage of patients with fecal calprotectin < 150 microgram/g", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Mean percent change of fecal calprotectin", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 to Week 4"
            }, 
            {
                "measure": "Mean percent change of fecal calprotectin", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 to Week 8"
            }, 
            {
                "measure": "Mean percent change of fecal calprotectin", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 to Week 12"
            }, 
            {
                "measure": "Percentage of patients in clinical remission and Percentage of clinical response patients", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Percentage of patients in clinical remission and Percentage of clinical response patients", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Percentage of patients in clinical remission and Percentage of clinical response patients", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}